Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
2.
Bioorg Med Chem Lett ; 17(20): 5647-51, 2007 Oct 15.
Article in English | MEDLINE | ID: mdl-17766113

ABSTRACT

A series of hybrid molecules containing the cyclopropylmethylamino side chain found in homotryptamine (1S,2S)-2c and an isosteric heteroaryl or naphthyl core were prepared and their binding affinities for the human serotonin transporter determined. The most potent isosteres were CN-substituted naphthalenes. These results demonstrate that isosteric aromatic cores which lack an H-bond donor site may be substituted for the indole nucleus without substantial loss in hSERT binding.


Subject(s)
Heterocyclic Compounds/chemistry , Heterocyclic Compounds/pharmacology , Selective Serotonin Reuptake Inhibitors/chemistry , Selective Serotonin Reuptake Inhibitors/pharmacology , Tryptamines/chemistry , Dopamine Plasma Membrane Transport Proteins/antagonists & inhibitors , Dopamine Plasma Membrane Transport Proteins/metabolism , Heterocyclic Compounds/chemical synthesis , Humans , Inhibitory Concentration 50 , Molecular Conformation , Norepinephrine Plasma Membrane Transport Proteins/antagonists & inhibitors , Norepinephrine Plasma Membrane Transport Proteins/metabolism , Selective Serotonin Reuptake Inhibitors/chemical synthesis , Structure-Activity Relationship
3.
Bioorg Med Chem Lett ; 14(16): 4245-8, 2004 Aug 16.
Article in English | MEDLINE | ID: mdl-15261279

ABSTRACT

The present studies have identified a series of aminotriazines as novel 5-HT(7) receptor antagonists. Compounds 10 and 17 have high affinity for the 5-HT(7) receptor and do not bind to either the 5-HT(2C) or 5-HT(6) receptors. These compounds produce no agonist effects by themselves, and shift the dose-response curve of 5-CT to the right in the manner of an antagonist.


Subject(s)
Receptors, Serotonin/drug effects , Serotonin Antagonists/pharmacology , Triazines/pharmacology , Dose-Response Relationship, Drug
4.
Bioorg Med Chem Lett ; 12(11): 1529-32, 2002 Jun 03.
Article in English | MEDLINE | ID: mdl-12031335

ABSTRACT

Bivalent doxorubicin (DOX)-dipeptides (16a-c) were prepared and conjugated to the monoclonal antibody BR96. The dipeptides are cleaved by lysosomal proteases following internalization of the resulting immunoconjugates. Conjugate 18b demonstrated antigen-specific in vitro tumor cell killing activity (IC(50)=0.2 microM) that was equipotent to DOX with a near doubling of drug molecules/MAb. Size exclusion chromatography showed 18b to be a noncovalent dimer that was formed immediately upon conjugation.


Subject(s)
Antibodies, Monoclonal/chemistry , Dipeptides/chemistry , Doxorubicin/analogs & derivatives , Doxorubicin/chemistry , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/pharmacology , Binding Sites , Cathepsin B/blood , Cathepsin B/metabolism , Chromatography, Gel , Dimerization , Dipeptides/pharmacology , Doxorubicin/chemical synthesis , Doxorubicin/immunology , Doxorubicin/pharmacology , Half-Life , Humans , Immunoconjugates/chemistry , Immunoconjugates/immunology , Immunoconjugates/pharmacology , Inhibitory Concentration 50 , Lung Neoplasms/drug therapy , Lysosomes/enzymology , Stereoisomerism , Sulfhydryl Compounds/chemistry , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...